Akebia Therapeutics to Participate in Piper Sandler 32nd Annual Virtual Healthcare Conference November 18, 2020 Akebia Therapeutics Ranked 10th Fastest-Growing Company in North America on Deloitte's 2020 Technology Fast 500™ Akebia Therapeutics Inc. said its investigational oral hypoxia-inducible factor prolyl hydroxylase inhibitor vadadustat reached primary and key secondary efficacy endpoints in … Making a difference by challenging the status quo. Each attorney is registered with registration number, full name, company name and address, phone number, email, year admitted, etc. Akebia Therapeutics, Inc. is an Alaska Business Corporation filed on October 27, 2020. Akebia Therapeutics Since our founding in 2007, Akebia (Nasdaq: AKBA) has been focused on achieving better outcomes for people with kidney disease. Needham & Company LLC began coverage on Akebia Therapeutics in a report on Tuesday, August 11th. Akebia Therapeutics Inc.’s Net Margin is presently recorded at -83.48. READ OUR COMPANY STATEMENT (8.10.20). CAMBRIDGE, Mass., Nov. 18, 2020 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that it ranked number 10 on Deloitte's Technology Fast 500™, a ranking of the 500 fastest-growing technology, media, telecommunications, life sciences and energy tech companies … Within Japan, Vadadustat is approved as a treatment for anemia due to CKD in both dialysis-dependent and non-dialysis dependent adult patients, and will be marketed by Mitsubishi Tanabe Pharma Corporation in Japan under the trade name VAFSEO™. The … Search jobs by location. Search jobs by category. Press Release reported on 10/12/20 that Thinking about buying stock in Akebia Therapeutics, Aileron Therapeutics, Riot Blockchain, Plug Power, or Translate Bio? Our team works to address complications of kidney disease. The company's filing status is listed as Good Standing and its File Number is 10146181. The analysts might have been a bit too bullish on Akebia Therapeutics, Inc. (NASDAQ:AKBA), given that the company fell short of expectations when it released its third-quarter results last week. Akebia Therapeutics, Inc. (NASDAQ:AKBA)’s Major holders. Akebia Therapeutics Inc ... we believe we have a significant opportunity to advance our mission and help address the unmet needs of the 500,000-plus adult patients with anemia due to … are currently affected by chronic kidney disease. We are a leader in the renal community – a fully integrated biopharmaceutical company with capabilities ranging from research through commercialization. The Registered Agent on file for this company is The Corporation Company and is located at 7700 E. Arapaphoe Road Suite 220, Centennial, CO 80112. Akebia Therapeutics. Akebia Therapeutics Inc. [AKBA]: Deeper insight into the fundamentals. Note Regarding Forward Looking Statements. It engages in the clinical development of compounds for the treatment of anemia and ischemia-related disorders. The company’s stock price has collected 0.85% of gains in the last five trading sessions. Akebia Therapeutics (AKBA) delivered earnings and revenue surprises of -82.61% and -21.20%, respectively, for the quarter ended September 2020. Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of proprietary therapeutics based on hypoxia inducible factor (HIF) biology for patients with kidney disease. Michel Dahan is Senior VP/COO at Akebia Therapeutics Inc. See Michel Dahan's compensation, career history, education, & memberships. You are leaving akebia.com, a website of Akebia Therapeutics, Inc. Akebia does not review or control the content of non-Akebia websites, and this hyperlink does not constitute an endorsement by Akebia of the site’s content. Note Regarding Forward Looking Statements. We use cookies in order to provide you with a better browsing experience. Akebia Therapeutics (AKBA) came out with a quarterly loss of $0.42 per share versus the Zacks Consensus Estimate of a loss of $0.23. Akebia Therapeutics, Inc. is a biopharmaceutical company. Akebia’s privacy procedures do not apply to the owners of a non-Akebia website. Akebia Therapeutics - Found 11 - 50 Employees, 6 Phone Numbers and 5 Emails. The company’s stock price has collected -30.19% of loss in the last five trading sessions. For patients in the U.S. taking a prescribed Akebia product, please visit AkebiaCares.com or call 855-686-8601 for assistance. For more information, please visit our website at www.akebia.com. Akebia Therapeutics Inc. (NASDAQ:AKBA) went down by -3.24% from its latest closing price compared to the recent 1-year high of $13.71. Akebia Therapeutics, Inc. is a Massachusetts Foreign Corporation filed on December 12, 2013. See the company profile for Akebia Therapeutics, Inc. (AKBA) including business summary, industry/sector information, number of employees, business … We are bold and optimistic as we work to better the life of each person impacted by kidney disease. Search jobs by category. Akebia Therapeutics. Operating Margin for any stock indicates how profitable investing would be, and Akebia Therapeutics Inc. [AKBA] shares currently have an operating margin of -85.46 and a Gross Margin at +56.61. Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. Akebia Therapeutics, Inc. is a biopharmaceutical company headquartered in Cambridge, Massachusetts, focused on delivering innovative therapies to patients with kidney disease through HIF biology. For all general inquiries, please contact: For employment verification, please visit Truework. The Registered Agent on file for this company is C T Corporation System and is located at 155 Federal St., Suite 700, Boston, MA 02110. The Cambridge, Massachusetts-based company said it had a loss of 42 cents per share. Search job openings at Akebia Therapeutics. Got it! BidaskClub upgraded shares of Akebia Therapeutics (NASDAQ:AKBA) from a sell rating to a hold rating in a research note issued to investors on Thursday morning, BidAskClub reports. See insights on Akebia Therapeutics including office locations, competitors, revenue, financials, executives, subsidiaries and more at Craft. AKBA Akebia Therapeutics Inc Current Report Filing (8-k) Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).. Search Business Operations. We use cookies in order to provide you with a better browsing experience. Search jobs by location. Kristen K. Sheppard, Esq VP, Investor Relations, Mercedes Carrasco Director, Corporate Communications media@akebia.com, Patrick Walsh VP, Business Development partnering@akebia.com, Susan Brady Manager, Advocacy & Corporate Communications sponsorships@akebia.com, Akebia Therapeutics to Participate in Piper Sandler 32nd Annual Virtual Healthcare Conference, Akebia Therapeutics Ranked 10th Fastest-Growing Company in North America on Deloitte's 2020 Technology Fast 500™, Global Phase 3 programme of vadadustat for treatment of anaemia of chronic kidney disease: rationale, study design and baseline characteristics of dialysis-dependent patients in the INNO2VATE trials, Akebia Therapeutics, Inc. 245 First Street, Suite 1400 Cambridge, MA 02142, +1 617.871.2098  phone +1 617.871.2099  fax. Show search filters Clear filters. © 2020 Akebia Therapeutics, Inc. All rights reserved. Vadadustat and other HIF-PHIs are based on Nobel Prize-winning science. On average, equities research analysts expect that Akebia Therapeutics will post -1.5 earnings per share for the current fiscal year. Akebia Therapeutics, Inc. is a growing biopharmaceutical company headquartered in Cambridge, Massachusetts, focused on the development and commercialization of therapeutics for patients with chronic kidney disease. The company offers Omacor for hypertriglyceridemia; and Actonel for osteoporosis. The company's File Number is listed as 208756903. Akebia Therapeutics Inc. [AKBA]: Deeper insight into the fundamentals. Akebia Therapeutics, Inc. () Stock Market info Recommendations: Buy or sell Akebia Therapeutics stock? Get the latest Akebia Therapeutics, Inc. (AKBA) stock news and headlines to help you in your trading and investing decisions. The company's filing status is listed as Active and its File Number is 0379092. Press Release reported on 10/26/20 that Akebia Therapeutics to Report Third Quarter 2020 Financial Results and Discuss Recent Business Highlights 12 talking about this. The company’s stock price has collected 0.85% of gains in the last five trading sessions. Akebia Therapeutics, Inc. is a Massachusetts Foreign Corporation filed on December 12, 2013. The company's filing status is listed as Active and its File Number is 0379092. Search Business Operations. CAMBRIDGE, Mass., Nov. 18, 2020 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that it ranked number 10 on Deloitte's Technology Fast 500™, a ranking of the 500 fastest-growing technology, media, telecommunications, life sciences and energy tech companies … The move came on solid volume too … Shares of Akebia Therapeutics (NASDAQ:AKBA) are plunging today, down 72.3% as of 11:15 a.m. EDT, after the company announced results from a … Akebia Therapeutics, Inc. AKBA was a big mover last session, as the company saw its shares rise nearly 7% on the day. The Registered Agent on file for this company is C T Corporation System and is located … Show search filters Clear filters. Akebia Therapeutics had a negative net margin of 113.35% and a negative return on equity of 55.64%. You are leaving akebia.com, a website of Akebia Therapeutics, Inc. Akebia does not review or control the content of non-Akebia websites, and this hyperlink does not constitute an endorsement by Akebia of the site’s content. The Registered Agent on file for this company is C T Corporation System and is located … search. Akebia Therapeutics (NASDAQ:AKBA) was downgraded by Zacks Investment Research from a "hold" rating to a "sell" rating in a research report issued to clients and investors on Friday, Zacks.com reports. We have both a commercially available medicine and a late stage oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), vadadustat, in global Phase 3 clinical development for the treatment of anemia due to CKD. Vadadustat and other HIF-PHIs are based on Nobel Prize-winning science. The average twelve-month pri About Akebia Therapeutics Akebia Therapeutics - Found 11 - 50 Employees, 6 Phone Numbers and 5 Emails. Vadadustat is an investigational drug that has not been approved by the U.S. Food and Drug Administration (FDA) or any regulatory authority for use outside of Japan. To learn more and to turn off cookies visit our Cookie Policy. Akebia Therapeutics Inc. [AKBA] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -16.61. Akebia Therapeutics Ranked 10th Fastest-Growing Company in North America on Deloitte's 2020 Technology Fast 500™ November 16, 2020 Global Phase 3 programme of vadadustat for treatment of anaemia of chronic kidney disease: rationale, study design and baseline characteristics of dialysis-dependent patients in the INNO2VATE trials Description. Address: 10151 CARVER RD STE 205 CINCINNATI OHIO 45242 UNITED STATES: Congressional District Four investment analysts have rated the stock with a hold rating and six have issued a buy rating on the company. Press Release reported on 10/12/20 that Thinking about buying stock in Akebia Therapeutics, Aileron Therapeutics, Riot Blockchain, Plug Power, or Translate Bio? This dataset includes 357 thousand attorneys registered with New York State, Office of Court Administration. close Create Job Alert. The Registered Agent on file for this company is C T Corporation System and is located … Akebia Therapeutics, Inc. manufactures biopharmaceutical products. Website www.akebia… Do the … Akebia Therapeutics serves customers in the United States. Chronic kidney disease is a serious and life-altering illness that is persistent, progressive, and irreversible. close Create Job Alert. Akebia Therapeutics. 245 First Street Suite 1100 Cambridge, MA 02142 United States. CAMBRIDGE, Mass., Nov. 3, 2020-- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted 6 newly-hired employees options to purchase an aggregate of 27,000 shares of Akebia's common stock on October 30, 2020, as inducements material to each such employee's entering into employment with Akebia. Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. With this latest performance, AKBA shares dropped by -75.81% in over the last four-week period, additionally sinking by -67.29% over the last 6 months – not to mention a drop of -44.53% in the past year of trading. Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company focused on the development and commercialization of therapeutics for people living with kidney disease. The company offers Omacor for hypertriglyceridemia; and Actonel for osteoporosis. Akebia Therapeutics (AKBA) delivered earnings and revenue surprises of -82.61% and -21.20%, respectively, for the quarter ended September 2020. © 2020 Akebia Therapeutics, Inc. All rights reserved. To learn more and to turn off cookies visit our Cookie Policy. Akebia Therapeutics, Inc. is a Colorado Foreign Corporation filed on December 10, 2013. By continuing to use this website you agree to our use of cookies. Akebia Therapeutics, Inc. Tab l e of C on te n ts P ar t I . According to Zacks, "Akebia Therapeutics Inc. is a biopharmaceutical company. The company's File Number is listed as 208756903. Akebia Therapeutics Inc. (NASDAQ:AKBA) went down by -2.20% from its latest closing price compared to the recent 1-year high of $13.71. If we look at who the major shareholders are, we find that insiders hold 3.18% of Akebia Therapeutics, Inc. shares while 78.98% of the shares are in the hands of institutional holders. The company's filing status is listed as Good Standing and its File Number is 20131708174. Akebia Therapeutics, Inc., a pharmaceutical company, focuses on treatments for ischemia and improvement of vascular disease. Cambridge, MA 02142 +1 617.871.2098 phone +1 617.871.2099 fax. 1-617-871-2098. Akebia Therapeutics Inc. AKBA) on Thursday reported a loss of $60 million in its third quarter. We are a fully integrated biopharmaceutical company. Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. Emerging growth company ☐ Akebia Therapeutics, Inc., a pharmaceutical company, focuses on treatments for ischemia and improvement of vascular disease. CAMBRIDGE, Mass., Nov. 18, 2020 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that it ranked number 10 on Deloitte's Technology Fast 500™, a ranking of the 500 fastest-growing technology, media, telecommunications, life sciences and energy tech companies … It focuses on the development and commercialization of proprietary therapeutics based on hypoxia … Akebia Therapeutics Inc.’s Net Margin is presently recorded at -83.48. The company’s stock price has collected -23.24% of loss in the last five trading sessions. Akebia Therapeutics Inc. (NASDAQ:AKBA) went down by -3.24% from its latest closing price compared to the recent 1-year high of $13.71. Akebia Therapeutics Announces First Commercial Launch of VAFSEO™ (vadadustat tablets), a New Oral Treatment for Anemia Due to Chronic Kidney Disease, in Japan ... Email Address * … Akebia Therapeutics, Inc. 245 First Street, Suite 1400. The … Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of renal therapeutics for patients with kidney diseases. F i n an c i al I n for mati on Item 1 – Financial Statements (Unaudited) Condensed Consolidated Balance Sheets … Press Release reported 16 hours ago that Akebia Therapeutics to Report Third Quarter 2020 Financial Results and Discuss Recent Business Highlights It engages in the clinical development of compounds for the treatment of anemia and ischemia-related disorders. Akebia Therapeutics has 324 employees at their 1 location and $335 M in annual revenue in FY 2019. +1 617.871.2099  fax. Akebia Therapeutics has 324 employees at their 1 location and $335 M in annual revenue in FY 2019. Akebia Therapeutics, Inc. manufactures biopharmaceutical products. Address. Create Job Alert Cancel. Akebia Therapeutics. Akebia Presents Results from INNO2VATE Global Phase 3 Program for Vadadustat at ASN Kidney Week, As a member of the renal community, the health of our patients and employees is our first priority. Akebia Therapeutics, Inc. AKBA was a big mover last session, as the company saw its shares rise nearly 7% on the day. The Company focuses on the development and commercialization of therapeutics based on hypoxia-inducible factor (HIF) biology. The Registered Agent on file for this company is C T Corporation System and is located at 155 Federal St., Suite 700, Boston, MA 02110. AKBA Akebia Therapeutics Inc Current Report Filing (8-k) Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).. Phone. Emerging growth company ☐ Akebia Therapeutics Inc. 245 1st St CAMBRIDGE MA 02142-1200 P: +1617.8712098 F: +1617.8712099 Akebia Therapeutics to Participate in Piper Sandler 32nd Annual Virtual Healthcare Conference, Akebia Therapeutics Ranked 10th Fastest-Growing Company in North America on Deloitte's 2020 Technology Fast 500™, Global Phase 3 programme of vadadustat for treatment of anaemia of chronic kidney disease: rationale, study design and baseline characteristics of dialysis-dependent patients in the INNO2VATE trials, Akebia Therapeutics, Inc. 245 First Street, Suite 1400 Cambridge, MA 02142, +1 617.871.2098  phone +1 617.871.2099  fax. Operating Margin for any stock indicates how profitable investing would be, and Akebia Therapeutics Inc. [AKBA] shares currently have an operating margin of -85.46 and a Gross Margin at +56.61. Each attorney is registered with registration number, full name, company name and address, phone number, email, year admitted, etc.
Liquid From Compost Tumbler, When To Harvest Vegetables, Best Wool Carpet Brands, Goodtime Parlor Banjo For Sale, Aveda Be Curly Curl Enhancer How To Use, Oceanside Harbor Surf Report, Film Logo Hd,